Vitamin D3 + K2 (Cholecalciferol + Menaquinone)
SupplementThe community overestimates the clinical evidence: while users consistently report subjective improvements [c1, c2], the scientific literature shows no significant effect on hard endpoints such as coronary artery calcification in large RCTs [s5]. Biomarker evidence (ucOC, dp-ucMGP) is strong; clinical relevance remains controversial [s8].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
The mechanistic synergy of D3 and K2 is well-founded: D3 increases calcium absorption, K2 (MK-7) directs it into bone rather than arteries. RCT data for bone turnover markers and modest BMD improvements is solid, but a large 2022 RCT found no reduction in arterial calcification — hard cardiovascular endpoints remain unproven. Anyone on vitamin K antagonists (warfarin/Marcumar) must not take K2 without medical supervision — this is a real, not theoretical, interaction. High-dose D3 (>2,000 IU/day) should always be guided by blood level monitoring.
Description
Synergistic combination of fat-soluble vitamin D3 (calcium absorption) and K2 (calcium directing into bone, vascular protection) for bone and cardiovascular health [s1, s2, s3].
Vitamin D3 (cholecalciferol) and vitamin K2 (preferably as menaquinone-7, MK-7) are fat-soluble vitamins that act synergistically in calcium metabolism [s1, s2]. Vitamin D3 increases intestinal calcium absorption and renal calcium reabsorption, as well as calbindin expression in the distal renal tubule [s3]. It simultaneously induces the synthesis of osteocalcin and matrix Gla protein (MGP) in bone and vascular tissue [s1, s2]. Vitamin K2 activates both protein classes via γ-glutamyl carboxylase-dependent carboxylation: carboxylated osteocalcin incorporates calcium into the bone matrix, while carboxylated MGP prevents calcium deposition in arteries and soft tissues [s1, s2, s4]. Without adequate K2, high-dose D3 may theoretically increase the calcium burden on vessels, as uncarboxylated MGP (dp-ucMGP) exerts no inhibitory function [s2, s4]. Clinical evidence for combined D3+K2 supplementation is heterogeneous: for bone mineral density, some RCTs with MK-7 show positive effects in postmenopausal women [s6], while others show no difference versus placebo [s7]. For cardiovascular endpoints (coronary artery calcification), a large 2022 RCT found no significant improvement with MK-7 + D3 [s5]. The synergistic effect on biomarkers (ucOC, dp-ucMGP) is well documented [s3, s4], but the clinical relevance for hard endpoints remains controversial. Vitamin D deficiency (25-OH-D < 50 nmol/L) is prevalent in the DACH region, making supplementation particularly reasonable during winter months. Combination with K2 is especially advisable at higher D3 doses (≥ 2,000 IU/day) to support calcium homeostasis [s1, s2, s10].
Legal Status (DE)
Marketable as an over-the-counter food supplement (NEM) in Germany, Austria, and Switzerland. The BfR recommends maximum levels of 20 µg/day (800 IU) for vitamin D3 and 25 µg/day for vitamin K2 (MK-7) in food supplements [s10, s11]. Higher-dose preparations (e.g., 2,000–5,000 IU D3) are available without prescription but exceed BfR recommendations. Products with vitamin K antagonist activity do not fall under this category.
Mechanism of Action
Following hepatic (25-hydroxylation) and renal (1α-hydroxylation) activation, vitamin D3 binds as 1,25-dihydroxycholecalciferol (calcitriol) to the vitamin D receptor (VDR). This leads to: (1) induction of calcium-binding proteins (calbindin) in the intestine → increased intestinal Ca²⁺ absorption [s3]; (2) enhancement of renal Ca²⁺ reabsorption in the distal tubule [s3]; (3) induction of osteocalcin and MGP synthesis in osteoblasts and vascular smooth muscle cells [s1, s2]. Vitamin K2 (MK-7) acts as an essential cofactor of γ-glutamyl carboxylase, which converts glutamate residues in vitamin K-dependent proteins to γ-carboxyglutamate (Gla) [s4]. Two key target proteins are: - Osteocalcin (OC): Upon carboxylation, it binds hydroxyapatite in the bone matrix and promotes mineralization [s1, s4]. - Matrix Gla protein (MGP): Carboxylated MGP inhibits crystallization of calcium phosphate in the vessel wall; uncarboxylated MGP (dp-ucMGP) is functionally inactive and serves as a biomarker for vitamin K insufficiency [s2, s4]. The synergy arises because D3 induces the synthesis of these proteins, while K2 ensures their functional activation through carboxylation [s1, s2]. MK-7, with a half-life of approximately 3 days, has substantially greater bioavailability than MK-4 (half-life < 1 hour) and is therefore better suited for once-daily supplementation [s4].
Dosing
Allgemeine Prävention / Winterergänzung
- Dose
- 800–2,000 IU vitamin D3 + 75–100 µg MK-7
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend (Oktober bis April, oder ganzjährig bei Mangel)
- Timing
- With a fat-containing meal (improves absorption of both vitamins)
- With food
- empfohlen
Knochengesundheit / Osteoporoseprophylaxe postmenopausal
- Dose
- 2,000 IU vitamin D3 + 180 µg MK-7
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Mindestens 3 Jahre (Studienprotokoll Knapen et al.)
- Timing
- With a fat-containing meal
- With food
- optional
Diabetes Typ 2 / Biomarkeroptimierung (ucOC-Reduktion)
- Dose
- 1,000 IU vitamin D3 + 100 µg MK-7
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 6 Monate (Studiendauer)
- Timing
- Morning with a meal
- With food
- empfohlen
EFSA: Tolerable total intake for vitamin D3 = 100 µg/day (4,000 IU/day) for adults [s9]. BfR recommends a maximum of 20 µg/day (800 IU) in food supplements [s11]. For vitamin K2 (MK-7), the BfR recommends a maximum of 25 µg/day in food supplements [s10]. The Endocrine Society considers up to 250 µg/day (10,000 IU) D3 clinically tolerable for deficiency correction under medical supervision [s9].
Both vitamins are fat-soluble – always take with a fat-containing meal. Before high-dose supplementation (>2,000 IU/day D3), 25-OH-D blood levels should be measured. MK-7 (all-trans) is preferred over MK-4 for once-daily dosing due to its longer half-life [s4].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Hyperkalzämie (Übelkeit, Erbrechen, Schwäche, Polyurie, Nierenkalzinose) Occurs with chronically excessive vitamin D3 intake (>10,000 IU/day over months). Vitamin D3 increases intestinal calcium absorption; excess leads to hypercalcemia. Case reports documented in Germany (Coimbra protocol) [s12]. | selten | schwer |
| Milde gastrointestinale Beschwerden (Übelkeit, Magendrücken) Occasionally reported at higher D3 doses (>4,000 IU/day); K2 does not contribute significantly to GI side effects [s9]. | gelegentlich | leicht |
| Müdigkeit, Benommenheit bei Therapiebeginn Reported by community users upon initiation of D3 supplementation; not well documented clinically [c1, c2]. | gelegentlich | leicht |
| Veränderung der INR / Antikoagulationseffektivität bei Vitamin-K-Antagonisten Vitamin K2 antagonizes vitamin K antagonists (e.g., warfarin/phenprocoumon) by competing for γ-glutamyl carboxylase. May reduce INR and increase thromboembolic risk [s13]. | häufig | schwer |
Contraindications
Interactions
Synergistic
Vitamin D3 promotes intestinal calcium absorption and the synthesis of calcium-regulating proteins, while Vitamin K2 as a cofactor activates carboxylation of osteocalcin and matrix Gla protein, thereby enhancing calcium deposition in bone; boron supports this process by inhibiting Vitamin D catabolism and modulating calcium metabolism, resulting in a synergistic improvement of bone mineralization.
Magnesium is essential for the conversion and activation of Vitamin D3 in the body. Without adequate magnesium, neither D3 nor K2 can be properly transported and utilized. The combination of all three nutrients synergistically supports bone density, calcium homeostasis, and cardiovascular health.
Magnesium is essential for the activation of Vitamin D3 and, together with K2, supports calcium utilization. Every form of magnesium benefits from this synergy.
Magnesium threonate also benefits from the synergy with Vitamin D3/K2 through mutual enhancement of absorption and activation.
Magnesium citrate supports the activation of Vitamin D3 and acts synergistically with K2 and D3 on bone and cardiovascular health.
Vitamin D3 enhances intestinal calcium absorption, while K2 ensures that absorbed calcium is deposited in bone rather than in arteries. This combination optimizes bone mineralization.
Caution
Vitamin K2 is a functional antagonist of vitamin K antagonists (e.g., warfarin, phenprocoumon), as it serves as a substrate for vitamin K epoxide reductase, promoting coagulation factor synthesis and thereby potentially attenuating the anticoagulant effect of vitamin K antagonists, necessitating close INR monitoring.
High-dose Vitamin D3 without adequate K2 can elevate serum calcium levels (hypercalcemia) and increase the risk of arterial calcification. K2 should therefore always be taken concomitantly at higher D3 doses.
Community Evidence
Top reported benefits
- Improved mood and energy (especially in winter)
- Perceived immune enhancement
- Combination with K2 as a safety measure at high D3 doses
- Improvement of serum vitamin D levels to target values
Top reported issues
- Fatigue or drowsiness at treatment initiation (transient)
- Uncertainty about optimal dosage (D3 amount)
- Lack of blood level monitoring before and during supplementation
- Fear of overdose at high doses (5,000–10,000 IU)
Community users in Germany discuss the interaction of K2 with Marcumar/warfarin extensively. Several users report a lack of medical counseling regarding this interaction. High doses (>5,000 IU/day) without blood level monitoring are criticized by more experienced community members [c1, c2, c3].
Scientific Sources
- Vitamin D and K: How They Work Together
Bolt Pharmacy (Redaktion) (2024). Bolt Pharmacy Health GuideCLink - Einnahme hoher Einzeldosen Vitamin D über Nahrungsergänzungsmittel im Abstand von Tagen oder Wochen birgt gesundheitliche Risiken
Bundesinstitut für Risikobewertung (BfR) (2024). BfR StellungnahmeALink - Hochdosierte Nahrungsergänzungsmittel mit Vitamin D können langfristig die Gesundheit beeinträchtigen
Bundesinstitut für Risikobewertung (BfR) (2023). BfR Stellungnahme 065/2023ALink - Vitamin-D3-Überdosierung nach Anwendung exzessiver Dosen im Rahmen des Coimbra-Protokolls
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2023). Drug Safety Mail 2023-48 (AkdÄ)CLink - Effect of vitamin K2 on the anticoagulant activity of warfarin
Gebuis EP, Ophuis AJMO, Russel FGM, et al. (2016). BMC Pharmacology and Toxicology / PMCCLink - Transcriptional regulation of matrix Gla protein
Farzaneh-Far A, Proudfoot D, Shanahan CM, Weissberg PL (2001). Trends in Cardiovascular MedicineBPMID:11374031 - Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk
Sørensen MK, Pedersen AB, Søndergaard TE, et al. (2020). AtherosclerosisBPMID:32422228DOI - Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease
Dalmeijer GW, van der Schouw YT, Magdeleyns E, et al. (2014). Arteriosclerosis, Thrombosis, and Vascular BiologyBPMID:24210635DOI - Pivotal role of boron supplementation on bone health: A narrative review
Rondanelli M, Faliva MA, Peroni G, Infantino V, Gasparri C, Iannello G, Perna S, Riva A, Petrangolini G, Tartara A (2020). Journal of Trace Elements in Medicine and BiologyBPMID:32540741DOI - Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial
McComsey GA, Minnich L, Kirby C, et al. (2025). NutrientsBLink - Vitamin D3 stimulates MGP synthesis, while vitamin K2 activates it through carboxylation
Remedys Nutrition (Redaktion) (2024). Remedys Nutrition BlogCLink - Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial
Rahimi Sakak F, Maranian M, Yeganeh MZ, et al. (2020). Nutrition JournalAPMID:32727476DOI - The Importance of Vitamin K and the Combination of Vitamins K and D for Calcium Metabolism and Bone Health: A Review
Maresz K (2024). NutrientsBDOI - Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
Vadin AS, Ngo DTM, Svingen GFT, et al. (2022). CirculationAPMID:35652341DOI - Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
Knapen MHJ, Drummen NE, Smit E, et al. (2013). Osteoporosis InternationalAPMID:23525894DOI - The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
Rønn SH, Harsløf T, Pedersen SB, et al. (2021). Osteoporosis InternationalAPMID:33030563DOI - Effects of vitamin K supplementation on bone mineral density at different sites and bone metabolism in the middle-aged and elderly population: a meta-analysis and systematic review of randomized controlled trials
Chen Y, Liu X, Chen L, et al. (2024). Frontiers in EndocrinologyADOI - Vitamin D - Health Professional Fact Sheet
National Institutes of Health (NIH), Office of Dietary Supplements (2024). NIH Office of Dietary SupplementsALink
Community Sources
Storage
Unopened
Store cool (15–25 °C), dry, and protected from light; do not refrigerate.
Opened
Keep container tightly closed; avoid moisture and direct sunlight.
Notes
Both vitamins are fat-soluble and light-sensitive. Oil-based drops should be used after opening within the manufacturer's stated period (typically 6–12 months).